The US Food and Drug Administration (FDA) plans to scrutinize the safety and efficacy of lab-developed tests — those designed, manufactured, and used in a single laboratory — far more thoroughly in the future.
Under a rule finalized in April, the FDA will treat facilities that develop and use lab tests as manufacturers and regulate tests as medical devices. That means that most lab tests will need an FDA review before going on sale.
The FDA will also impose new quality standards, requiring test manufacturers to report adverse events and create a registry of lab tests under the new rule, which will be phased in over 4 years.
FDA officials have been concerned for years about the reliability of commercial lab tests, which have ballooned into a multibillion-dollar industry.
Consumer groups have long urged the FDA to regulate lab tests more strictly, arguing that the lack of scrutiny allows doctors and patients to be exploited by bad actors such as Theranos, which falsely claimed that its tests could diagnose multiple diseases with a single drop of blood.
"When it comes to some of these tests that doctors are recommending for patients, many doctors are just crossing their fingers and relying on the representation of the company because nobody is checking" to verify a manufacturer's claims, said Joshua Sharfstein, MD, vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, Baltimore.
Nearly 12,000 Labs Making Medical Tests
Although the FDA estimates there are nearly 12,000 labs manufacturing medical tests, agency officials said they don't know how many tests are being marketed. The FDA already requires that home test kits marketed directly to consumers, such as those used to detect COVID-19, get clearance from the agency before being sold.
"There's plenty of time for industry to get its act together to develop the data that it might need to make a premarket application," said Peter Lurie, MD, PhD, a former associate commissioner at the FDA. In 2015, Lurie led a report outlining some of the dangers of unregulated lab tests.
For the average physician who orders lab tests, nothing is going to immediately change due to the final rule, said Lurie, now president of the Center for Science in the Public Interest, a nonprofit consumer watchdog.
"Tomorrow, this will look just the same as it does today," Lurie said. "For the next 3 years, the companies will be scurrying behind the scenes to comply with the early stages of implementation. But most of that will be invisible to the average practitioner."
Lurie predicts the FDA will focus its scrutiny on tests that pose the greatest potential risk to patients, such as ones used to diagnose serious diseases or guide treatment for life-threatening conditions. "The least significant tests will likely get very limited, if any, scrutiny," said Lurie, adding that the FDA will likely issue guidance about how it plans to define low- and high-risk tests. "My suspicion is that it will be probably a small minority of products that are subject to full premarket approval."
Lab Industry Groups Push Back
But imposing new rules with the potential to affect an industry's bottom line is no easy task.
The American Clinical Laboratory Association, which represents the lab industry, said in a statement that the FDA rule will "limit access to scores of critical tests, increase healthcare costs, and undermine innovation in new diagnostics." Another industry group, the Association for Molecular Pathology, has warned of "significant and harmful disruption to laboratory medicine."
The two associations have filed separate lawsuits, charging that the FDA overstepped the authority granted by Congress. In their lawsuits, groups claim that lab tests are professional services, not manufactured products. The groups noted that the Centers for Medicare & Medicaid Services (CMS) already inspects lab facilities. CMS does not assess the tests' quality or reliability.
A recent Supreme Court decision could make those lawsuits more likely to succeed, said David Simon, JD, LLM, PhD, an assistant professor of law at the Northeastern University School of Law.
In the case of Loper Bright Enterprises v. Raimondo, decided in June, justices overturned a long-standing precedent known as Chevron deference, which required courts to defer to federal agencies when interpreting ambiguous laws. That means that courts no longer have to accept the FDA's definition of a device, Simon said.
"Because judges may have more active roles in defining agency authority, federal agencies may have correspondingly less robust roles in policymaking," Simon wrote in an JAMA editorial co-authored with Michael J. Young, MD, MPhil, of Harvard Medical School, Boston, and published last month.
The Supreme Court ruling could pressure Congress to more clearly define FDA's ruling in regulating lab tests, Simon and Young wrote.
Members of Congress first introduced a bill to clarify the FDA's role in regulating lab tests, called the VALID Act, in 2020. The bill stalled and, despite efforts to revive it, still hasn't passed.
FDA officials have said they remain "open to working with Congress," noting that any future legislation about lab-developed tests would supersede their current policy.
In an interview, Simon noted the FDA significantly narrowed the scope of the final rule in response to comments from critics who objected to an earlier version of the policy proposed last year. The final rule carves out several categories of tests that won't need to apply for "premarket review."
Notably, a "grandfather clause" will allow some lab tests already on the market to continue being sold without undergoing FDA's premarket review process. In explaining the exemption, FDA officials said they did not want doctors and patients to lose access to tests on which they rely. But Lurie noted that because the FDA views all these tests as under its jurisdiction, the agency could opt to take a closer look "at a very old device that is causing a problem today."
The FDA also will exempt tests approved by New York State's Clinical Laboratory Evaluation Program, which conducts its own stringent reviews. And the FDA will continue to allow hospitals to develop tests for patients within their healthcare system without going through the FDA approval process, if no FDA-approved tests are available.
Hospital-based tests play a critical role in treating infectious diseases, said Amesh Adalja, MD, an infectious diseases specialist and senior scholar at the Johns Hopkins Center for Health Security. For example, a large research hospital treating a patient with cytomegalovirus may need to develop its own test to determine whether the infection is resistant to antiviral drugs, Adalja said.
"With novel infectious disease outbreaks, researchers are able to move quickly to make diagnostic tests months and months before commercial laboratories are able to get through regulatory processes," Adalja said.
To help scientists respond quickly to emergencies, the FDA published special guidance for labs that develop unauthorized lab tests for disease outbreaks.
Medical groups such as the American Hospital Association and Infectious Diseases Society of America remain concerned about the burden of complying with new regulations.
"Many vital tests developed in hospitals and health systems may be subjected to unnecessary and costly paperwork," said Stacey Hughes, executive vice president of the American Hospital Association, in a statement.
Other groups, such as the American Society of Clinical Oncology, praised the new FDA policy. In comments submitted to the FDA last year, the cancer group said it "emphatically supports" requiring lab tests to undergo FDA review.
"We appreciate FDA action to modernize oversight of these tests and are hopeful this rule will increase focus on the need to balance rapid diagnostic innovation with patient safety and access" Everett Vokes, MD, the group's board chair, said in a statement released after the FDA's final rule was published.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.